# TRANSCEND-NHL-001 (NCT02631044)

> Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02631044
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Juno Therapeutics, a Subsidiary of Celgene
- Conditions: Non-Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Mantle-cell Lymphoma; Primary Mediastinal B-cell Lymphoma
- Interventions: JCAR017 (lisocabtagene maraleucel) single-dose schedule; JCAR017 (lisocabtagene maraleucel) 2-dose schedule
- Enrollment: 387
- Primary outcome: Treatment-related adverse events (AEs) as assessed by CTCAE v4.03
- Primary outcome: Dose-limiting toxicities of JCAR017
- Primary outcome: Objective response rate (ORR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 21
- Podcasts: 6
- YouTube: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=transcend-nhl-001-nct02631044

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02631044", "email": "<work email>"}; the inbox owner confirms by the emailed link.